Table 1.
Summary of clinical features of the patients with gross hematuria after receiving COVID-19 vaccine.
| Study | Age/sex | Country | Comorbidities | New onset or relapse | Types of vaccine | Vaccine dose | Onset time (D, W) | Creatinine (mg/dL) | Biopsy | 24 h urine protein (g/d) {uPCR [g/g]} | Treatment | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Presentation | Follow up | Presentation | Follow up | ||||||||||
| Tan et al[11] | 41/F | SG | GDM | N | mRNA (Pfizer) | 2 | D2 | 1.73 | - | Yes | {2.03} | - | Steroid + CTX |
| Tan et al[11] | 60/F | SG | HPL | N | mRNA (Pfizer) | 2 | D2 | 6.12 | - | Yes | {7.58} | - | Steroid + CTX + PE |
| Hanna et al[4] | 17/M | US | No | N | mRNA (Pfizer) | 2 | D1 | 1.78 | 1.20 | Yes | {1.75} | {1.20} | Steroid |
| Kudose et al[3] | 50/F | US | HTN, obesity, APS | N | mRNA (Moderna) | 2 | D2 | 1.70 | - | Yes | {2.00} | - | - |
| Kudose et al[3] | 19/M | US | No | N | mRNA (Moderna) | 2 | D2 | 1.20 | - | Yes | - | - | - |
| Park et al[5] | 22/F | US | IgA vasculitis | N | mRNA (Moderna) | 2 | D2 | 0.80 | 0.80 | No | 0.4 | 0.27 | Conservative |
| Park et al[5] | 39/F | US | No | N | mRNA (Moderna) | 2 | D2 | 0.80 | 0.80 | No | 0.9 | - | Conservative |
| Park et al[5] | 50/M | US | HTN | N | mRNA (Moderna) | 2 | D1 | 1.54 | 1.24 | Yes | 3.56 | 2.2 | Conservative |
| Park et al[5] | 67/M | US | HTN | N | mRNA (Moderna) | 1 | M1 | 2.90 | 1.40 | Yes | 2.1 | 0.09 | Steroid |
| Abramson et al[6] | 30/M | US | No | N | mRNA (Moderna) | 2 | D1 | 1.02 | 1.03 | Yes | {0.80} | {0.43} | Conservative |
| Klomjit et al[8] | 38/M | US | No | N | mRNA (Pfizer) | 2 | 2W | 1.60 | - | Yes | 0.32 | - | Conservative |
| Klomjit et al[8] | 44/M | US | No | N | mRNA (Moderna) | 1 | 2W | 2.50 | 3.60 | Yes | 14 g | 5.6 | Steroid |
| Klomjit et al[8] | 66/M | US | No | N | mRNA (Moderna) | 1 | 2W | 1.50 | 1.40 | Yes | 1.2 g | 0.3 | Steroid |
| Klomjit et al[8] | 62/M | US | No | N | mRNA (Pfizer) | 2 | 6W | 2.20 | 2.00 | Yes | 0.9 g | 0.2 | Conservative |
| Niel and Florescu[12] | 13/F | LU | No | N | mRNA (Pfizer) | 1 | D1 | 3.57 | 0.86 | Yes | 3.88 | - | Steroid + HD |
| Hanna et al[4] | 13/M | US | IgAN, T1DM | R | mRNA (Pfizer) | 2 | D1 | 1.31 | 0.66 | No | {1.07} | {0.86} | Conservative |
| Rahim et al[7] | 52/F | US | IgAN | R | mRNA (Pfizer) | 2 | D1 | 0.80 | 0.80 | No | 2.41 | 1.44 | Conservative |
| Plasse et al[10] | - | US | IgAN | R | mRNA (Pfizer) | 2 | D1 | 3.53 | Baseline | No | 3 | Baseline | Steroid |
| Plasse et al[10] | - | US | IgAN | R | mRNA (Pfizer) | 2 | D1 | 1.16 | - | No | 0.92 | - | Conservative |
| Negrea and Rovin[2] | 38/F | US | IgAN | R | mRNA (Moderna) | 2 | D1 | - | - | No | 0.82 | 1.4 | Conservative |
| Negrea and Rovin[2] | 38/F | US | IgAN | R | mRNA (Moderna) | 2 | D1 | - | - | No | 0.59 | 0.4 | Conservative |
| Perrin et al[9] | 22/M | FRA | IgA vasculitis | R | mRNA (Moderna) | 1, 2 | D2, 25 | 0.40 | 0.4 | No | 0.34 | 0.4 | Conservative |
| Perrin et al[9] | 41/F | FRA | IgAN-Grafting | R | mRNA (Pfizer) | 1 | D2 | - | - | No | 0.47 | 0.41 | Conservative |
| Perrin et al[9] | 27/F | FRA | IgA -HD | R | mRNA (Pfizer) | 2 | D2 | HD | HD | No | 1.9 | 1.2 | Conservative |
| Klomjit et al[8] | 19/M | US | IgAN | R | mRNA (Moderna) | 2 | 1W | 0.76 | - | No | 0.61 | - | Conservative |
APS = antiphospholipid syndrome, CTX = cyclophosphamide, D = day, Dose = which dose of COVID-19 was injected, F = female, GDM = gestational diabetes, HD = hemodialysis, HPL = hyperlipidemia, HTN = hypertension, IgAN = IgA nephropathy, M = male, PE = plasma exchange, TB = tuberculosis, T1DM = type 1 diabetes, W = week.